Ocumension Invests $15.7 Million In EyePoint of the US
publication date: Jan 4, 2021
Shanghai's Ocumension Therapeutics invested $15.7 million in its US partner, EyePoint Pharma of Massachusetts. Previously, Ocumension acquired China rights to EyePoint's two commercial products: Yutiq®, a treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and Dexycu®, a postoperative inflammation treatment following ocular surgery. In July, Ocumension completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion. More details....
Stock Symbols: (HK: 1477) (NSDQ: EYPT)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.